Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2009-06-10 Capital/Financing Update
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Securities to be Released from Escrow 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a notice regarding the release of securities from escrow, specifying the number of shares and options to be released on a certain date. It references Listing Rule 3.10A, which relates to securities and shareholding disclosures. The document does not contain financial statements, management discussion, or detailed financial data. It is an announcement about a capital-related event (release of securities from escrow), which fits best under capital or financing updates. The document length is short (1788 characters), and it is not a report or a certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2009-06-10 English
Appendix 3B 7 pages ?Kb
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about securities issuance, quotation application, and related warranties to the ASX (Australian Securities Exchange). The content focuses on the issuance and quotation of new shares, including number, class, and terms of securities, as well as compliance with relevant laws and ASX requirements. There are no financial statements, earnings data, management discussion, or audit information. The document is regulatory in nature, related to capital market activities, specifically new share issuance and quotation. This matches the definition of a Share Issue/Capital Change announcement (SHA). The document length is 9481 characters, which is substantial and contains detailed information, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is SHA with high confidence.
2009-06-10 English
Quotation of Shares Previously Released from Escrow 7 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about securities issuance, quotation application, and related warranties to the ASX (Australian Securities Exchange). The content focuses on the announcement and procedural details of a securities issue and quotation rather than financial results, management discussion, or regulatory certifications. The document length is 9480 characters, which is substantial but the content is clearly an announcement related to capital changes, specifically new securities issuance and quotation application. This matches the definition of a Share Issue/Capital Change filing rather than a full financial report or other categories. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change).
2009-06-10 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and notes on compliance and accounting standards. The report covers a quarter ended 31 March 2009, indicating it is a quarterly financial report. The length of the document (6681 characters) and the presence of substantive financial data confirm it is a full quarterly report rather than a brief announcement or certification. The document matches the characteristics of an Interim / Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. Q3 2009
2009-04-28 English
Shareholder Update after completion of PK studies under IND 3 pages ?Kb
Capital/Financing Update Classification · 85% confidence The document is a shareholder update from HalcyGen Pharmaceuticals Limited discussing the results of pivotal pharmacokinetic studies related to their drug SUBA-Itraconazole following FDA IND allowance. It includes clinical study results, regulatory strategy, market information, and licensing interest. There are no financial statements, earnings data, or detailed financial analysis. The document is an announcement/update about clinical and regulatory progress rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a corporate update aimed at shareholders about clinical program progress and regulatory plans, which aligns best with a Capital/Financing Update (CAP) as it relates to development progress and potential market impact relevant to investors. Confidence is high given the content and context.
2009-03-02 English
Half Yearly Report and Accounts 17 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half-year report' and explicitly states it is a half-year financial report for the period ended 31 December 2008. It contains detailed financial statements including income statement, balance sheet, cash flow statement, notes to the financial statements, directors' report, and auditor's review report. The content includes comprehensive financial data and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2009
2009-02-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.